Recent clinical trials have shown that bisphosphonate drugs improve breast cancer patient survival independent of their antiresorptive effects on the skeleton. However, because bisphosphonates bind rapidly to bone mineral, the exact mechanisms of their antitumor action, particularly on cells outside of bone, remain unknown. Here, we used real-time intravital twophoton microscopy to show extensive leakage of fl uorescent bisphosphonate from the vasculature in 4T1 mouse mammary tumors, where it initially binds to areas of small, granular microcalcifi cations that are engulfed by tumor-associated macrophages (TAM), but not tumor cells. Importantly, we also observed uptake of radiolabeled bisphosphonate in the primary breast tumor of a patient and showed the resected tumor to be infi ltrated with TAMs and to contain similar granular microcalcifi cations. These data represent the fi rst compelling in vivo evidence that bisphosphonates can target cells in tumors outside the skeleton and that their antitumor activity is likely to be mediated via TAMs.
INTRODUCTION
For more than two decades, bisphosphonate (BP) drugs have been the fi rst-line therapy for the treatment and prevention of skeletal-related events in cancer patients with multiple myeloma and bone metastases, because they rapidly target the skeleton and inhibit osteoclastic bone resorption. In osteoclasts, nitrogen-containing BPs (N-BP), such as zoledronic acid (ZOL), act intracellularly by inhibiting farnesyl diphosphate (FPP) synthase, a key enzyme in the mevalonate pathway. This prevents the biosynthesis of isoprenoids necessary for the prenylation, and hence membrane localization and function, of small GTPases essential for osteoclastic bone resorption ( 1 ) . Because of their high affi nity for bone, the bioavailability of BPs in soft tissues is assumed to be very low. However, in various preclinical models, N-BPs have been shown to exert striking osteoclast-independent antitumor effects, including on tumors located outside the skeleton ( 2 ) . Indeed, several large clinical trials in patients with breast cancer and multiple myeloma have also indicated recently that
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Simon Junankar N-BPs have benefi ts beyond inhibiting bone resorption ( 3 ) . Zometa (ZOL) signifi cantly increased disease-free survival when used alongside adjuvant endocrine therapies in women with early breast cancer ( 4 ) and in postmenopausal patients with breast cancer when used as adjuvant therapy with aromatase inhibitors or other endocrine therapies ( 5, 6 ) . Importantly, ZOL also decreased the locoregional recurrence of tumors outside the skeleton ( 5 ). These fi ndings are supported by several meta-analyses indicating signifi cant benefi ts in disease-free and overall survival as well as decreased local and distant tumor recurrence. Moreover, epidemiologic studies also suggest that long-term BP therapy decreases the risk of invasive breast cancer ( 7 ) . Nevertheless, there is ongoing controversy over whether N-BPs exert direct or indirect antitumor effects in vivo , and the cellular targets and mechanisms involved, particularly in cells outside the skeleton, have yet to be elucidated. Furthermore, 99m technetium-labeled methylenebisphosphonate ( 99m Tc-MDP, a radionuclide bone scanning agent commonly used to detect bone metastases) is recognized to accumulate in some extraskeletal tumors, including neuroblastomas, sarcomas, and breast carcinomas, although its exact mechanism of uptake in soft-tissue tumors is unclear ( 8 ) . MDP is the simplest chemical form of BP and, like N-BPs, binds avidly to calcium ions and is internalized into cells by endocytosis. Therefore, to determine how BPs localize to soft-tissue tumors to exert their antitumor activity, we used intravital two-photon microscopy, together with fl ow cytometric analysis, to determine the cell types capable of internalizing a fl uorescently labeled N-BP in a soft-tissue tumor model. We used the syngeneic 4T1 mouse model of breast cancer because treatment with ZOL has previously been shown to reduce visceral metastases in this model ( 9 ) . Finally, to confi rm our fi ndings, we analyzed the uptake of Tc-MDP by the primary breast tumor in the preoperative bone scan of a patient and examined the postoperative resected tumor for microcalcifi cations and infi ltration by tumor-associated macrophages (TAM).
RESULTS

N-BP Accumulates in Mammary Tumor Tissue via Leaky Tumor Vasculature
To identify the cell types capable of internalizing N-BP in tumors outside the skeleton and the route of cellular uptake, we fl uorescently conjugated the N-BP risedronate to form a bone-seeking but pharmacologically inactive analogue (AF647-RIS; ref. 10 ) and examined its localization in mice bearing syngeneic 4T1 mammary tumors. Infrared imaging of tumor explants 24 hours after subcutaneous injection showed that AF647-RIS was detectable in whole 4T1 mammary tumors ( Supplementary Fig. S1A ) where it localized to the tumor periphery ( Supplementary Fig.  S1B ). Two-photon imaging of tumor explants revealed that AF647-RIS was present intracellularly in cells located in and beneath the tumor capsule ( Supplementary Fig. S1C ), a region enriched for F4/80 + TAMs ( Supplementary Fig. S1D  and S1E ).
On the basis of these observations, we next examined the dynamic distribution and cellular uptake of AF647-RIS in real-time in 4T1 mammary tumors of live mice using intravital two-photon microscopy. Before imaging, TAMs were labeled in vivo with anti-F4/80 mAb conjugated to FITC. Imaging of second-harmonic generation by collagen fi bers revealed that tumors were supplied by a dense, subcapsular network of tortuous capillaries and small blood vessels closely associated with F4/80 + TAMs ( Fig. 1A ; Supplementary Movie S1). Immediately following intravenous injection, AF647-RIS could be visualized fl owing into the vascular bed of the mammary tumors and leaking into the surrounding tumor tissue. In contrast, intravital imaging of the normal mammary fat pad of mice that did not receive 4T1 tumor cells showed rapid transit of AF647-RIS through the blood vessels in less than 5 minutes and absence of any capillary leak into mammary tissue ( Fig. 1A and B ; Supplementary Movie S2). The same fi ndings were obtained using the fl uorescently labeled N-BP 
TAMs Phagocytose N-BP-Coated Microcalcifi cations
Unbound AF647-RIS persisted in 4T1 tumor blood vessels and mammary tumor tissue for more than 15 minutes after injection of mice ( Fig. 1A and B ) and was observed to rapidly (within minutes) bind 2-to 5-μm granular clumps. These microstructures were calcifi ed, because they bound the calciumseeking dye calcein in vivo as well as N-BP ( Fig. 2A ) . Image analysis of a 425 × 425 × 150 μm volume (i.e., 51 optical sections) of tumor showed that 43% of N-BP colocalized with calcein, with a Pearson correlation of 0.4 ( Supplementary Fig. S2 ). These structures closely resembled the small granules of microcalcifi cation (distinct from the larger calcifi cations present in the lumen of mammary ducts) that we detected histologically in sections of random human breast cancer tissue by von Kossa staining ( Supplementary Movie S3), whereas AF647-RIS bound to microcalcifi ed granules was engulfed by phagocytosis ( Fig. 3B ; Supplementary Movie S4) . Notably, we did not observe any uptake in any non-F4/80-labeled cells such as epithelial cells. Imaging of mice 24 hours following AF647-RIS administration indicated that the bulk of the AF647-RIS was localized in the cytoplasm of F4/80 + cells, confi rming the uptake by TAMs ( Fig. 3C ; Supplementary Movie S5).
We also examined the uptake of fl uorescently labeled N-BP in mice bearing subcutaneous B16.F10 melanomas. Although we also observed some leakage of N-BP from tumor capillaries, in contrast with 4T1 tumors, we did not observe any binding to granular calcifi cations or retention of N-BP in the tumor tissue ( Supplementary Fig. S3A ). Although we did detect some calcein staining in the B16 tumors, this was considerably less than in the 4T1 tumors ( Supplementary Fig. S3B ). Consistent with this, FACS analysis showed little uptake of N-BP by TAMs in B16 tumors ( Supplementary Fig. S3C ). This suggests that the presence of microcalcifi cations in tumors strongly enhances the effi ciency of uptake of N-BP by TAMs.
N-BP Is Effi ciently Internalized In Vivo by TAMs but Not by Tumor Cells
To confi rm the phenotype of the cells responsible for uptake of N-BP, we performed multiparameter fl ow cytometric analysis of enzymatically digested, single-cell suspensions . 3D ). There was minor uptake of AF647-RIS by EpCAM + mammary epithelial cells ( Fig. 3E ) , with a small shift in mean fl uorescence intensity (MFI) that was below the limit of detection of our intravital imaging modalities ( Fig. 1A and B ) . The bulk of AF647-RIS, however, was taken up by a major subpopulation of CD45 + leukocytes ( Fig. 3E ) . Analysis for F4/80 expression confi rmed that these cells were F4/80 + TAMs ( Fig. 3F and G ) , confi rming the results of the intravital imaging studies ( Fig. 3C ; Supplementary Movie S5). Signifi cantly, quantifi cation of the MFI showed a near 5-fold increase in AF647-RIS MFI in CD45 +
F4/80
+ TAMs compared with a <2-fold increase in tumor epithelial cells and no increase in CD45 + F4/80 neg TILs ( Fig.  3G and H ) . Further analysis showed that the F4/80 + TAMs that internalized AF647-RIS were also CD11b + ( Fig. 3I ) . Collectively, these data identify TAMs as the cell type targeted by N-BP in mammary tumors.
Clinicopathologic Correlation of Bisphosphonate Uptake in Human Breast Cancer with Microcalcifi cations and TAMs
A 51-year-old female patient presented with a grade 1 invasive duct carcinoma associated with ductal carcinoma in situ and focal lymphovascular invasion (whole tumor size, 16 mm). A routine bone scintigraphy scan using Tc-MDP and multimodal single-photon emission computed tomography (SPECT)/ CT imaging revealed clear uptake of the radionuclide in the mammary carcinoma ( Fig. 4A ) . Sections of the resected tumor of this patient showed extensive CD68 + and CD163 + macrophage infi ltration ( Fig. 4Bi and ii ) . Furthermore, von Kossa staining revealed the presence of small, granular calcifi cations within the mammary tumor tissue ( Fig. 4Biii ) and in adjacent benign tissue ( Fig. 4Biv and v ) that were similar in size and appearance to those observed to bind N-BP and be internalized by TAMs in the mouse 4T1 tumors. Some of these granular microcalcifi cations in the human tumor tissue were also closely associated with, or even appeared to have been internalized by, CD68 + or CD163 + macrophages ( Fig. 4Bii/ iii and iv/v ).
DISCUSSION
The exact mechanism underlying the in vivo antitumor activity of N-BPs has been highly controversial because it is not clear which cell types internalize these drugs in tumors, particularly outside the skeleton. Other studies have shown that N-BP treatment can affect the mevalonate pathway in subcutaneous or peritoneal tumors in mouse models in vivo , but these reports did not identify the exact cell types involved (12) (13) (14) . Our data show unequivocally that, in 4T1 mammary tumors, N-BP is rapidly and effi ciently internalized by TAMs rather than tumor cells. This is consistent with reports that ZOL treatment reduces the number of TAMs in mouse models of mammary and cervical cancer ( 15, 16 ). It appears that TAMs have a selective ability to internalize N-BPs that is shared with other myeloid lineage cells such as peripheral blood and bone marrow monocytes, peritoneal macrophages, and osteoclasts ( 17 ) , and is most likely related to the capacity of these cells for pinocytosis and phagocytosis of calciumcontaining complexes (such as microcalcifi cations), because there is no evidence for any other specifi c transport mechanisms for cellular uptake of these drugs ( 18 ) . Indeed, engulfment of N-BP-coated microcalcifi cations may be the major route of uptake by TAMs in vivo because we observed little uptake of N-BP by TAMs in B16 tumors that lacked extensive binding of N-BP to microcalcifi cations.
Small, granular microcalcifi cations are common in human breast tumors because we identifi ed their presence in 40% of the tissue samples examined. In mouse 4T1 tumors, microcalcifi ed granules were also found to be present throughout the tumor tissue; the particular localization and retention of AF647-RIS in the tumor periphery presumably refl ect the high density of leaky vessels in this region. The time course of the distribution and cellular uptake of AF647-RIS in 4T1 tumors (within 30 minutes of injection) is entirely consistent with the rapid localization of 99m Tc-MDP in breast tumors observed in some patients by scintigraphic imaging ( 19 ) . Our observations therefore identify the likely mechanism of soft-tissue tumor localization of 99m Tc-MDP in humans by a similar mechanism to that observed in mice, that is, via leaky tumor vessels and binding to granular microcalcifi cations that are engulfed by TAMs. This provides a mechanistic explanation for a phenomenon that was fi rst described 40 years ago ( 20 ) but remains poorly characterized.
In osteoclasts and macrophages, inhibition of FPP synthase by N-BPs and the subsequent loss of prenylation of small GTPases affect numerous processes, including polarization, adhesion, migration, vesicular traffi cking, proliferation, and survival ( 1 , 21 ) . It is highly likely that N-BP treatment also affects multiple functions of TAMs in vivo by inhibiting protein prenylation. TAMs have emerged as powerful promoters of tumor growth and metastasis ( 22 ) , and extensive macrophage infi ltration in many tumor types is associated with poor patient prognosis ( 23 ) . Our studies indicate that the antitumor activity of N-BPs observed in preclinical models and in clinical trials is likely mediated indirectly through uptake of these drugs by TAMs and possibly other myeloid lineage cells, leading to their functional impairment and depletion, rather than by direct effects on tumor cells per se . These observations provide a further rationale for the use of N-BP as adjuvant cancer therapy in patients with early-stage disease.
METHODS
SPECT / CT Imaging of Patients
Radionuclide bone scans were performed using 900MBq Tc-MDP (technetium-99m-methylene diphosphonate; RadPharm) followed by multimodal SPECT/CT imaging after 3 hours using a GE Discovery NM/CT 670 with BrightSpeed Elite16 slice CT and Advanced Elite NXT SPECT detectors.
Preclinical Mouse Tumor Models
Immunocompetent BALB/c mice ages 6 to 8 weeks were obtained from Australian BioResources + macrophage that appears to contain intracellular microcalcifi cations; scale bars, 50 μm.
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on December 18, 2017. © 2015 American Association for Cancer cancerdiscovery.aacrjournals.org Downloaded from were inoculated subcutaneously into the fl anks of C57/BL6 mice. Mice were administered a single dose of N-BP (0.9 mg/kg AF647-RIS or 0.7 mg/kg OsteoSense 680) or 70 mg/kg calcein 10 to 14 days after tumor cell inoculation.
Intravital Two-Photon Microscopy of 4T1 Mammary Tumors
We used a Zeiss 7MP two-photon microscope (Carl Zeiss) excited by a Chameleon Vision II Ti:Sa laser (Coherent Scientifi c) with fi lters and detectors as described previously ( 24 ) . Intravital two-photon microscopy of mammary fat pad and 4T1 tumors was based on the method for imaging the medullary surface of inguinal lymph nodes ( 25 ) . See Supplementary Methods for additional details.
Flow Cytometry
Mice with palpable mammary tumors received a single s.c. injection of N-BP (0.9 mg/kg AF647-RIS or 0.7 mg/kg OsteoSense 680). Twenty-four hours later, the mice were perfused with PBS and euthanased. Tumors were mechanically dispersed and enzymatically digested (Collagenase Blend L; Sigma) using a gentleMACS (Milltenyi Biotech) tissue dissociator, incubated with DNase (1 mg/ mL; Sigma), then passed through a 70-μm nylon strainer (BD Biosciences). Erythrocytes were lysed using ammonium chloride, and the remaining cells were washed once in PBS, blocked with anti-CD16/32 (eBiosciences) for 10 minutes on ice, then stained with antibodies to CD45 (APC-AF750, from eBiosciences), F4/80 (FITC, from UCSF Hybridoma Core Facility), and EpCAM (PerCP-Cy5.5, from BioLegend), before analysis on a LSRII SORP fl ow cytometer using BD FACS DIVA software. Data were analyzed using FlowJo software (Treestar Inc.). For detection of AF647-RIS uptake, cells from the tumors of vehicle-treated animals were used as controls for background fl uorescence. Fluorescence due to AF647-RIS uptake was measured as the geometric mean in the R670-nm channel, in CD45
Histology
Ethics approval was granted for the use of pathology specimens and cognate clinicopathologic data (Human Research Ethics Committee of St. Vincent's Hospital, Sydney, NSW, Australia). For von Kossa staining of microcalcifi cations, 5-μm formalin-fi xed, paraffi n-embedded sections of tumor were dewaxed and hydrated with distilled water, and then incubated in 1% silver nitrate in bright light for 1 hour. Sections were then incubated in 5% sodium thiosulphate for 5 minutes and counterstained with 1% toluidine blue for 30 seconds. Slides were then dehydrated and cleared before mounting in Eukitt mounting medium. Serial sections were immunostained for CD163 (clone 10D6; Novocastra) or CD68 (Ventana predilute KP1 antibody) using a standard protocol on a Ventana XT machine with CC1 antigen retrieval, brown chromogen, and hematoxylin counterstain. Images were captured using a Leica DM 6000 Power Mosaic microscope with a DFC310FX camera. See Supplementary Methods for additional details of immunostaining.
Ethical Statement
Written, informed consent was obtained from the patient for the use of deidentifi ed SPECT/CT images. Animal experiments were approved by the Garvan Institute of Medical Research/St. Vincent's Hospital Animal Experimentation Ethics Committee (AEC 12_41).
Statistical Analysis
The unpaired, two-sided Student t test with Welch correction was performed using Prism software (GraphPad).
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